<DOC>
	<DOCNO>NCT01986192</DOCNO>
	<brief_summary>The EINSTEIN program show oral rivaroxaban effective safe treatment prevention recurrent venous thrombosis pulmonary embolism deep vein thrombosis patient FDA approve rivaroxaban prevention treatment deep vein thrombosis ( Nov 2 2012 ) . Recently , catheter-directed thrombolysis significantly reduce post-thrombotic syndrome , center introduce catheter-directed thrombolysis treat proximal ( i.e , iliofemoral ) DVT . However , EINSTEIN program exclude patient deep vein thrombosis treat vena cava filter fibrinolytic agent current episode thrombosis . Although catheter-directed thrombolysis ( CDT ) pharmacomechanical thrombolysis accept treatment choice iliofemoral DVT , thrombolysis inherent risk bleeding . Therefore , patient complete CDT stabilize least 24 hour thrombolysis include study . Also , investigator want explore efficacy safety rivaroxaban patient iliofemoral DVT catheter-directed thrombolysis and/or vena cava filter insertion and/or venous stent insertion compare outcomes warfarin treatment alone . This study pilot study establish safety efficacy parameter study .</brief_summary>
	<brief_title>Prevention Recurrence After Thrombolysis Acute Iliofemoral Venous Thrombosis ( PRAIS ) Study</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Age 1875 year Onset symptom within past 21 day Objectively verify ( CT venography ) deep vein thrombosis localize iliofemoral segment Complete catheterdirected thrombolysis and/or vena cava and/or venous stent insertion Informed consent Incomplete catheterdirected thrombolysis If patient receive single dose warfarin randomization contraindicate anticoagulant treatment another indication warfarin estimate glomerular filtration rate MDRD equation &lt; 30ml/min clinically significant liver disease ( acute hepatitis , chronic active hepatitis , cirrhosis ) Alanine aminotransferase &gt; 3time high upper limit normal range Bacterial endocarditis Active bleeding high risk bleed Pregnancy breastfeed Concomitant use strong cytochrome P450 3A4 inhibitor inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>anticoagulation</keyword>
	<keyword>pharmacomechanical thrombolysis</keyword>
	<keyword>aspiration thrombectomy</keyword>
</DOC>